This article was originally published on PharmaTimes http://www.pharmatimes.com/news/new_lung_cancer_indication_for_keytruda_combo_okd_in_eu_1281600

MSD’s anti-PD-1 therapy Keytruda has been approved for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for first-line treatment of adults with metastatic squamous non-small cell lung cancer (NSCLC).

Related Posts